For comparison, injectable tirzepatide produces 15 to 22.5% body weight loss in clinical trials over 72 weeks at optimal doses
In trials and real-world experience, people have used GLP-1 medications safely for many years
The maximum dose produced the highest average results, but the incremental benefit over 10 mg was relatively modest, about 1.1 additional percentage points of body weight loss
During open enrollment, carefully estimate your anticipated GLP-1 medication costs for the upcoming year to determine appropriate FSA contribution levels or consider building your HSA savings to help manage these expenses
In a recent online survey, N = 600 patients with T2D were asked to provide their treatment preferences regarding a once-daily oral GLP-1RA compared with a once-weekly injectable GLP-1RA
The oral versus injection comparison shows that oral formulations may have different absorption profiles, which could be relevant for patients on medications that affect GI motility
